• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

Abstract The European Resuscitation Council (ERC) and the European Society of Intensive
Care Medicine (ESICM) have collaborated to produce these post-resuscitation care …

Risk stratification scheme. Risk stratification aiming at assessing the risk of VAs and SCD in
patients with MVP, involving two phases based on the clinical and imaging context and the …

Despite major advancements in cardiovascular medicine, sudden cardiac death (SCD)
continues to be an enormous medical and societal challenge, claiming millions of lives …

Purpose Genetic testing has advanced significantly since the publication of the 2011
HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the …

Background Genetic testing following sudden cardiac death (SCD) is currently guided by
autopsy findings, despite the inherent challenges of autopsy examination and mounting …

Background There is no established screening approach for hypertrophic cardiomyopathy
(HCM). We recently developed an artificial intelligence (AI) model for the detection of HCM …

In the early nineties, few years before the birth of Europace, the clinical and scientific world
of familial arrhythmogenic conditions was revolutionized by the identification of the first …

Sinus node dysfunction may be either transient (reversible/physiological) due to the
involvement of the autonomic nervous system or pharmaceuticals, or chronic due to …